Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Alberto Bedogni"'
Autor:
Rodolfo Mauceri, Martina Coppini, Massimo Attanasio, Alberto Bedogni, Giordana Bettini, Vittorio Fusco, Amerigo Giudice, Filippo Graziani, Antonia Marcianò, Marco Nisi, Gaetano Isola, Rosalia Maria Leonardi, Giacomo Oteri, Corrado Toro, Giuseppina Campisi
Publikováno v:
BMC Oral Health, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the preve
Externí odkaz:
https://doaj.org/article/185f61d4913c42b29a195474295eecf1
Autor:
Vittorio Fusco, Giuseppina Campisi, Paola Carcieri, Franca Fagioli, Oscar Bertetto, Michele Davide Mignogna, Alberto Bedogni
Publikováno v:
Oral, Vol 2, Iss 2, Pp 137-147 (2022)
On the 8th and 9th of May 2021, an online conference was organized to connect Italian physicians, dentists and oral care specialists, students, nurses, psychologists, dental hygiene experts, and other professionals to discuss controversial issues abo
Externí odkaz:
https://doaj.org/article/6830087b47c24b88928230df018b3ef6
Publikováno v:
Oral, Vol 2, Iss 1, Pp 41-48 (2022)
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patients. In contrast to high-doses antiresorptive therapy, denosumab has a transient effect on the inhibition of the bone remodeling process, suggesting t
Externí odkaz:
https://doaj.org/article/dc16b80bd64f489ca607aa71ae6c2f9d
Publikováno v:
Head & Face Medicine, Vol 17, Iss 1, Pp 1-4 (2021)
Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragilit
Externí odkaz:
https://doaj.org/article/a538b01478574f6ba72b861dd11b8236
Autor:
Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni
Publikováno v:
Dentistry Journal, Vol 6, Iss 3, p 42 (2018)
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need furthe
Externí odkaz:
https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e
Autor:
Alberto Bedogni, Rodolfo Mauceri, Vittorio Fusco, Francesco Bertoldo, Giordana Bettini, Olga Di Fede, Antonio Lo Casto, Claudio Marchetti, Vera Panzarella, Giorgia Saia, Paolo Vescovi, Giuseppina Campisi
Despite being one of the most recently studied oral diseases, MRONJ remains a condition with uncertain and controversial issues. The aim of this updated version of the position paper on MRONJ developed by the Italian Societies of Oral Pathology and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c74bc02c2b3851ff191bc7a7f884e21
https://doi.org/10.32388/pbuj6z
https://doi.org/10.32388/pbuj6z
Autor:
Rodolfo Mauceri, Rita Coniglio, Antonia Abbinante, Paola Carcieri, Domenico Tomassi, Vera Panzarella, Olga Di Fede, Francesco Bertoldo, Vittorio Fusco, Alberto Bedogni, Giuseppina Campisi
Publikováno v:
Supportive Care in Cancer. 30:6429-6440
Purpose The prevention and early diagnosis of medication-related osteonecrosis of the jaw (MRONJ) is fundamental to reducing the incidence and progression of MRONJ. Many in the field believe that dental hygienists should play an integral role in prim
Autor:
Giordana Bettini, Giorgia Saia, Piero Franco, Stefano Valsecchi, Laura Tognin, Enrico Alexandre, Alberto Bedogni
Publikováno v:
Qeios.
Background: Currently, the standard design of the skin component of abdominal soft-tissue flaps recommended for head and neck reconstruction encompasses the upper and lower periumbilical region to include the maximum number of myocutaneous perforator
Publikováno v:
Head & Face Medicine, Vol 17, Iss 1, Pp 1-4 (2021)
Head & Face Medicine
Head & Face Medicine
Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragilit